Guides

LL-37 Peptide: Research, Handling and Cost

LL-37 is a peptide your own body makes. That doesn't make the vial version well understood: the human trial record is short, mostly topical, and mixed.

Written and fact-checked by the Good Supplements research team7 min readUpdated November 19, 2026
BioLongevity Labs logo

Exclusive code

15% OFF

ATLAS15 takes 15% off any BioLongevity Labs order, including BPC-157, TB-500 and the GLOW blend. Black Friday is 27 November; we update this the day the sale goes live.

The short version

  • LL-37 is the only cathelicidin humans make, a 37-amino-acid antimicrobial peptide cut from a precursor protein called hCAP18.
  • Most of the research is in vitro or in mice. The human trials are small, mostly topical wound studies, and the largest one missed its main endpoint.
  • The FDA has said it lacks the safety information to know whether LL-37 would harm people when given as a drug, and it still can't be compounded under 503A.
  • BioLongevity's LL-37 (5mg) is $94.97, or $80.72 with ATLAS15, checked 18 November 2026. It ships as a lyophilised powder for research use only.
  • Read the COA closely before ordering. The published purity certificate has a blank lot field, and its trace carries another compound's label.

What LL-37 is

LL-37 is a short protein fragment from the human immune system. Its name comes from its first two amino acids, both leucine, and its length of 37 residues.

It's the active end of a larger precursor, hCAP18, which is encoded by the CAMP gene. When the precursor is cut, LL-37 is released. A 2006 review in Biochimica et Biophysica Acta describes it as the only cathelicidin-derived antimicrobial peptide found in humans, made in skin, gut, airway and testis cells and by several kinds of white blood cell.

Chemically, it's strongly positive and folds into a helix with one oily face and one charged face. That shape lets it sit in bacterial membranes, which carry a negative charge, and break them open. The same review lists other roles: damping or provoking inflammation, drawing immune cells to a wound, binding bacterial endotoxin, and helping skin close over a wound.

Vitamin D is part of the story too. A 2006 Science paper showed that when human macrophages detect bacteria, they switch on vitamin D machinery that in turn induces cathelicidin and kills tuberculosis bacteria in the dish.

What the published research covers

Most LL-37 papers sit in three groups, and it helps to keep them separate.

Lab studies make up the bulk. These test LL-37 against bacteria, fungi and biofilms in culture, and its signalling in cultured human cells. They show what the molecule can do in a controlled setting. They don't show what a vial does in a person.

Animal and disease-mechanism work is where things get complicated, because LL-37 doesn't only fight infection. In psoriasis, a 2007 Nature study found LL-37 binds the body's own DNA and lets immune cells react to it, a route into autoimmune-type inflammation. In rosacea, researchers reported abnormally high cathelicidin in patients' facial skin, and injecting the rosacea-type fragments into mice increased skin inflammation.

So the molecule cuts both ways. In a wound it may help. In skin already prone to inflammation, more of it is linked to worse disease. Our overview of peptides for inflammation covers how often that double edge shows up across the category.

The human data, such as it is

There are a handful of human trials, and nearly all apply LL-37 to the skin.

The first was a 2014 trial in venous leg ulcers: 34 people, four weeks of twice-weekly topical LL-37 or placebo. The two lower concentrations shrank ulcers faster than placebo; the highest concentration did no better than placebo. No safety concerns were reported.

The follow-up was bigger and less encouraging. The HEAL LL-37 phase IIb trial, published in 2021, enrolled 148 patients with hard-to-heal leg ulcers. Across the whole group, LL-37 didn't improve healing compared with placebo. A post hoc look at patients with large wounds found a benefit. Post hoc subgroup results are a reason to run another trial, and the authors said as much.

A 2023 Indonesian trial in diabetic foot ulcers used an LL-37 cream for four weeks and found more granulation tissue than with placebo. It didn't lower inflammatory markers or bacterial counts.

Injected LL-37 has been tested in a phase 1 melanoma trial, given straight into skin tumours. A 2018 case report from that programme describes a patient who developed multiple wart-like and blistering skin lesions about 45 days in. They cleared within two months of stopping. That's one patient, but it's also most of what's published about injecting it.

We found no published human trial of LL-37 injected under the skin for general health, immunity or longevity, which is how it's usually discussed online.

Safety unknowns

The FDA put cathelicidin LL-37 on its Category 2 list of bulk substances that may present significant safety risks in compounding. Its stated reasons were possible immune reactions for some routes, difficulty characterising the peptide and its impurities, and a lack of safety information to know whether it would cause harm in people.

In 2026 the agency said it would take LL-37 and eleven other peptides off that list, because the nominations had been withdrawn. That's a procedural change. LL-37 still isn't eligible for compounding under section 503A, and no LL-37 drug is approved.

The open questions are the ones you'd expect for a molecule that touches immunity: whether repeated exposure provokes antibodies, what it does in people with psoriasis, rosacea or autoimmune conditions, and what impurities in a research-grade vial do. Nobody has published answers. Our guides on whether peptides are safe and peptide side effects set out the general risks of unregulated vials.

How LL-37 is sold

LL-37 is sold online as a research chemical: a freeze-dried powder in a sealed vial, labelled not for human consumption. Sellers can't legally market it as a treatment, so any page promising immune or skin benefits is a red flag in itself.

Prices vary a lot. In our vendor data, 5mg vials run from about $35 to about $95. The spread mostly reflects how much testing a seller publishes and how recent it is, which is why the certificate matters more than the sticker price. Our guide to buying research peptides explains what a usable certificate of analysis looks like.

BioLongevity's LL-37: price, COA and what we'd ask

BioLongevity Labs lists LL-37 (5mg) at $94.97, the same price we saw on 17 November. With the code ATLAS15 it comes to $80.72, about $16 per milligram.

LL-37 wasn't part of BioLongevity's bioregulator markdowns when we checked on 18 November 2026. Shipping is free over $400, and orders before 12 PM Pacific ship the same business day.

The page lists ≥99% purity, third-party testing and US manufacture. Two certificates are linked from it. One is an endotoxin test by BioRegen dated 19 November 2025, for lot 16-3-45954, showing under 0.05 EU/mL against a 0.25 limit. That one's clear and lot-specific.

The purity certificate needs a closer read. It's BioRegen report #10179, analysed 28 March 2025, reporting 99.94% purity and a conforming identity test. But the lot number field is blank and no quantity was measured.

On top of that, the chromatogram is labelled "Cardiogen-03", with a main peak that fits a molecule of roughly 489 daltons. LL-37 weighs about 4,493. It may well be a template mix-up, but it means the published trace doesn't show LL-37.

So before you order, email BioLongevity and ask for the purity COA that matches the lot you'll receive. A good vendor sends it without fuss. Our BioLongevity Labs review covers the rest of its testing record, and the discount code page tracks what ATLAS15 and the 27 November Black Friday sale do to prices.

ProductList priceWith ATLAS15Per mg with codeBuy
LL-37 (5mg)$94.97$80.72$16.14Shop

BioLongevity LL-37 price, checked 18 November 2026

Storage and reconstitution

BioLongevity's handling note is standard for a freeze-dried peptide: keep the sealed vial at -20°C, away from light and moisture. Once reconstituted, keep it at 2 to 8°C and use it promptly. For longer storage, split it into single-use portions and freeze them, since repeated freezing and thawing damages peptides. Our peptide storage guide explains why each step matters.

The listing says LL-37 dissolves in water. The arithmetic of reconstitution is simple: 5mg in 2 mL gives 2.5 mg per mL, and our peptide calculator does the conversion for any vial size and volume. We don't give dosing guidance. The published human protocols were topical concentrations in wound gels and creams, and they don't translate to a vial.

If you're comparing compounds on the same order, our upcoming Cartalax guide covers one of BioLongevity's bioregulators, which sit in a very different, mostly Russian evidence base.

Before you go

15% OFF

Don't check out without it. ATLAS15 takes 15% off any BioLongevity Labs order, including BPC-157, TB-500 and the GLOW blend. Black Friday is 27 November; we update this the day the sale goes live.

Common questions

LL-37 is the only human cathelicidin, a 37-amino-acid antimicrobial peptide released from the precursor protein hCAP18. Your skin, gut, airways and white blood cells make it. The version sold online is a synthetic copy sold for research use.

This article is educational and reflects published research and vendor policies as of November 19, 2026. It is not medical advice, and nothing here recommends using a research chemical outside its stated purpose. Talk to a doctor or pharmacist before starting any supplement, especially if you are pregnant, nursing, managing a chronic condition, or taking prescription medication.

Keep reading